Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

What Was Tested

Researchers studied Amylin (Islet Amyloid Polypeptide) in the context of fat loss, obesity & body recomposition in this randomized controlled trial publication.

Who Took Part

The study group was 411 subjects.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, single-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

Neither the subjects nor the staff measuring them knew who was on Amylin (Islet Amyloid Polypeptide), so expectations could not easily colour the readings.

Only one side, usually the subjects, was kept unaware of whether Amylin (Islet Amyloid Polypeptide) was given.

The comparison arm used a placebo, so changes seen with Amylin (Islet Amyloid Polypeptide) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Amyloid, Body Mass Index, Body Size, Hypoglycemic Agents, Islet Amyloid Polypeptide, Life Style and Weight Loss.

What This Means in Plain Language

The paper is a randomized, double-blind and single-blind study of Amylin (Islet Amyloid Polypeptide) in 411 subjects in people with fat loss, obesity & body recomposition.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetes care), a journal based in United States.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, Fat loss, obesity & body recomposition research.